SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin informs about press release

05 May 2026 Evaluate
Lupin has informed that it enclosed a Press Release titled ‘Lupin Receives US FDA Approval for Glycerol Phenylbutyrate Oral Liquid’.

The above information is a part of company’s filings submitted to BSE.

Lupin Share Price

2340.35 -11.55 (-0.49%)
22-Jun-2026 15:20 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1864.00
Dr. Reddys Lab 1291.15
Cipla 1414.10
Zydus Lifesciences 1086.20
Lupin 2340.35
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: